enoxacin has been researched along with Koch's Disease in 2 studies
Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.
enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Enoxacin (ENX) showed a moderate degree of activities in vitro against Mycobacterium tuberculosis in modified Saunton medium and modified Lowenstein-Jensen Medium with MICs from 1 to 8micrograms/ml." | 7.69 | [Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis]. ( Li, H; Liu, S; Xu, G, 1995) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 5.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| "Enoxacin (ENX) showed a moderate degree of activities in vitro against Mycobacterium tuberculosis in modified Saunton medium and modified Lowenstein-Jensen Medium with MICs from 1 to 8micrograms/ml." | 3.69 | [Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis]. ( Li, H; Liu, S; Xu, G, 1995) |
| "Moxifloxacin was effective against mutant strain GyrB D500N, with the lowest MIC (0." | 1.36 | Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. ( Aubry, A; Chauffour, A; Farinotti, R; Fernandez, C; Jarlier, V; Lott, MC; Poissy, J; Veziris, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Poissy, J | 1 |
| Aubry, A | 1 |
| Fernandez, C | 1 |
| Lott, MC | 1 |
| Chauffour, A | 1 |
| Jarlier, V | 1 |
| Farinotti, R | 1 |
| Veziris, N | 1 |
| Xu, G | 1 |
| Li, H | 1 |
| Liu, S | 1 |
2 other studies available for enoxacin and Koch's Disease
| Article | Year |
|---|---|
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
Topics: Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Enoxacin; Fluoroquinolones; Gatifloxacin; | 2010 |
[Comparison of in-vitro and in-vivo activities of enoxacin and ofloxacin against the Mycobacterium tuberculosis].
Topics: Animals; Antitubercular Agents; Enoxacin; Female; Male; Mice; Microbial Sensitivity Tests; Mycobacte | 1995 |